Norway· NO-ID_C736429D-77C6-4765-8D8D-2DF9FE439C69

Adcetris

A brentuximab vedotin product containing brentuximab vedotin, registered in Norway by Takeda Pharma A/S (1). The same ATC class is registered in 13 of our 19 countries.

ATC L01FX05

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedAdcetrisATCL01FX05REGISTER NO.NO-ID_C736429D-77C6-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Brentuximab vedotin is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FX05 (brentuximab vedotin), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 8 of them publish a price we can compare per daily dose

Brentuximab vedotin · ATC L01FX05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of brentuximab vedotin costs, country by country.

Normalised to the WHO defined daily dose (6 mg), the median price runs from $10.73 in Finland to $468.90 in Switzerland — a ×44 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Brentuximab vedotin · price per daily dose (6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$468.90
  • FI Finland$10.73
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Brentuximab Vedotin
Manufacturer
Takeda Pharma A/S (1)
Country
Norway (NO)
ATC code
L01FX05
ATC class
Brentuximab vedotin
Defined daily dose
6 mg, P
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_varenummer
    132488
    50
    NOK 37760.2
  • no_merkevare_id
    ID_C736429D-77C6-4765-8D8D-2DF9FE439C69
  • gtin
    7046261324885

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

535 interactions on record for brentuximab vedotin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Brentuximab vedotin · interactions on record

535 records

  • 33 severe
  • 502 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ClotrimazoleA01AB18moderate
  • RolapitantA04AD14moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Brentuximab vedotin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brentuximab vedotin products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Adcetris
  • Liechtenstein · Adcetris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ff61116e-467b-4e2f-9a9d-7f8d4efec75b
GET /v1/drugs/ff61116e-467b-4e2f-9a9d-7f8d4efec75b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
  "source": "fest",
  "status": "A",
  "atc_name": "Brentuksimabvedotin",
  "merkevare_id": "ID_C736429D-77C6-4765-8D8D-2DF9FE439C69",
  "name_form_strength": "Adcetris pulv til kons til inf væske, oppl 50 mg",
  "prescription_group": "C"
}

See everything about brentuximab vedotin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.